Ovarian Cancer Epithelial

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS trial_result · 2019-01-10
Clinical Trial Update: Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors [Phase 1]
Phase 1 trial of talazoparib in advanced or recurrent solid tumors shows safety data and preliminary activity; results posted.